Rain Oncology Inc. Common Stock
RAIN
RAIN was delisted on the 25th of January, 2024.
59 hedge funds and large institutions have $184M invested in Rain Oncology Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 22 increasing their positions, 9 reducing their positions, and 2 closing their positions.
750% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 2
144% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 9
28% more funds holding
Funds holding: 46 → 59 (+13)
9% more capital invested
Capital invested by funds: $169M → $184M (+$15.1M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
41% less call options, than puts
Call options by funds: $720K | Put options by funds: $1.23M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$13.4M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$4.31M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.96M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$2.31M |
| 5 |
GC
GMT Capital
Atlanta,
Georgia
|
+$1.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$23.7M |
| 2 |
PA
Perceptive Advisors
New York
|
-$7.72M |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$2.62M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$1.25M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$203K |
RAIN Hedge Fund Activity: Q1 2023 in Review
59 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Rain Oncology Inc. Common Stock (RAIN) for Q1 2023, worth a combined $184M — up 8.9% from $169M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new RAIN positions and 2 closed out — a net gain of 15 holders — while 22 added to existing stakes and 9 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $13.4M. The largest seller was Deerfield Management, cutting an estimated $23.7M.
- 59 institutional investors held Rain Oncology Inc. Common Stock (RAIN) as of Q1 2023, up from 46 in Q4 2022.
- Funds reported $184M of Rain Oncology Inc. Common Stock stock for Q1 2023, up 8.9% quarter-over-quarter.
- 17 funds opened new Rain Oncology Inc. Common Stock positions in Q1 2023 and 2 closed out, a net change of +15 holders.
- The largest Rain Oncology Inc. Common Stock buyer in Q1 2023 was Adage Capital Partners, an estimated $13.4M added.
- The largest Rain Oncology Inc. Common Stock seller in Q1 2023 was Deerfield Management, an estimated $23.7M sold.
Based on aggregated 13F filings for Q1 2023.